Daewoong Pharmaceutical is responsible for the domestic supply of the real-time inpatient monitoring system 'thynC,' which has become the first domestically produced digital healthcare device to obtain insurance reimbursement under 'remote heart rate monitoring (EX871).' Remote heart rate monitoring refers to the use of technology to remotely monitor a patient's heart condition.
On the 3rd, Daewoong Pharmaceutical held a press conference at the JW Marriott Hotel Dongdaemun Square to introduce thynC and its vision for digital healthcare. In addition to EX871, thynC is also covered by existing insurance reimbursements for transcutaneous blood oxygen saturation measurement (E7230), electrocardiogram bedside detection (E6544), and 24-hour blood pressure measurement tests (E6548).
ThynC is a real-time remote monitoring system for hospitalized patients developed by Seers Technology. Previously, Seers Technology signed a contract with Daewoong Pharmaceutical for domestic supply in March of last year.
ThynC is a system that supports medical staff in continuously monitoring patients' conditions and responding immediately through wireless network equipment and artificial intelligence wearable diagnostic devices. It analyzes and manages patients' real-time biometric signals using wearable biosensors and artificial intelligence (AI) algorithms.
The wearable biosensor measures biometric signals such as electrocardiograms, body temperature, and oxygen saturation, while AI analyzes this data and relays it to medical staff in real time. It enhances the efficiency of nursing staff and provides tailor-made monitoring solutions for various inpatient environments including general wards and intensive care units.
Lee Young-shin, CEO of Seers Technology, noted, 'ThynC can detect particularly critical conditions such as cardiac arrest, sepsis, and falls, providing early warnings that enhance patient safety.' He added, 'In a situation where there is a lack of interns and nurses, it will play an important role in enhancing the efficiency of medical settings and improving the quality of patient management.' Lee emphasized, 'This acquisition of reimbursement is a significant milestone recognizing thynC's technological capabilities,' stating that 'it will enable medical institutions to adopt thynC more actively.'
Starting with this acquisition of insurance reimbursement, Daewoong Pharmaceutical plans to integrate Sky Labs' ring-type continuous blood pressure monitor 'Cartvipi' with thynC within the first half of this year. This aims to further expand digital healthcare technology and accelerate the establishment of a smart medical environment.
Daewoong Pharmaceutical has introduced a variety of innovative devices, including the continuous glucose monitoring system 'Freestyle Libre,' the wearable electrocardiogram device 'Mobicare,' the ring-type continuous blood pressure monitor 'Cartvipi,' and the AI-assisted diagnostic solution for blindness diseases 'Whiskey.' Mobicare has achieved the number one market share in the domestic wearable electrocardiogram market and is utilized in over 840 hospitals nationwide. Within four months of its release, Cartvipi has been tested in over 1,200 hospitals.
Jo Byeong-ha, head of the marketing department at Daewoong Pharmaceutical, stated, 'Currently, thynC is being used in 10 hospitals, and we plan to expand our supply not only to general hospitals but also to semi-general hospitals.' He added, 'We will do our utmost to optimize the health management of hospitalized patients across various departments, including cardiology, neurology, respiratory medicine, surgery, emergency medicine, and oncology, allowing medical staff to manage patients more efficiently.'
Jo noted, 'We are now advancing towards predicting and managing diseases based on accumulated health data.' He added, 'Daewoong Pharmaceutical aims to introduce and disseminate innovative, data-driven health management solutions to realize personalized health management and contribute to the improvement of public health.'